"Complement C5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX.
| Descriptor ID |
D003182
|
| MeSH Number(s) |
D12.776.124.486.274.450
|
| Concept/Terms |
Complement C5- Complement C5
- C5, Complement
- C5 Complement
- Complement, C5
- Complement 5
- Complement Component 5
- Component 5, Complement
Complement C5, Precursor- Complement C5, Precursor
- C5, Precursor Complement
- Precursor Complement C5
- Pro-C5
- Pro C5
- Pro-complement 5
- Pro complement 5
- Precursor C5
- C5, Precursor
|
Below are MeSH descriptors whose meaning is more general than "Complement C5".
Below are MeSH descriptors whose meaning is more specific than "Complement C5".
This graph shows the total number of publications written about "Complement C5" by people in this website by year, and whether "Complement C5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement C5" by people in Profiles.
-
The allosteric modulation of complement C5 by knob domain peptides. Elife. 2021 02 11; 10.
-
Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients. Eur J Immunol. 2021 03; 51(3):634-647.
-
Complement C5 inhibition in patients with COVID-19 - a promising target? Haematologica. 2020 12 01; 105(12):2847-2850.
-
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Nov 19; 21(1):934.
-
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020 10 29; 136(18):2080-2089.
-
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol. 2020 11; 220:108598.
-
COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience. Br J Haematol. 2020 10; 191(1):e1-e4.
-
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders. Am J Case Rep. 2020 Sep 12; 21:e927418.
-
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020 10; 219:108555.
-
Haploidentical Hematopoietic Stem Cell Transplant Complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant From the Same Donor With No Immunosuppression but C5 Inhibition. Transplantation. 2019 02; 103(2):e48-e51.